| Craig A. Wheeler |
Wheeler joined Momenta as CEO in September of 2006. He led the company
through the launch of its first complex drug products, including the first generic versions
of LOVENOX® and once-daily COPAXONE®. He has overseen the company’s
growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur
of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta
the number one company in their annual Globe 100 survey of top performing companies.
Prior to joining Momenta, Wheeler was President of Chiron BioPharmaceuticals
and a senior member of The Boston Consulting Group’s health care practice. He
began his career at Merck’s MSDRL research unit. Wheeler is currently a member of
the Board of Directors of Amicus Therapeutics as well as the Generic Pharmaceutical
Association where he previously served as Chairman from 2014 to February
2016. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals
where he helped oversee the transition of the company from a research-based
platform to a fully integrated CNS pharmaceutical company until 2015 when it was
acquired by Otsuka Pharmaceuticals for $3.5 billion.
675 West Kendall Street
Cambridge, MA 02142
617 395-5158
Craig_wheeler@comcast.net